Retelleptine (SR-95325 B) is an antitumoral agent. This ellipticine derivative exhibits high toxicity against several rodent tumor models. Retelliptine is thought to intercalate with DNA and inhibit topoisomerase II during DNA replication. A phase I study reported possible drug-related toxicity sporadically such as somnolence, bronchospasm, dry mouth, and vomiting.

Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.

Etisulergine (CQ 32-084) is an ergoline derivative. Etisulergine stimulates both dopamine D1- and D2-receptors, antagonizes alpha-adrenergic and serotonin 5-HT2 receptors. Etisulergine demonstrated antiparkinsonian activity in patients.

Auriclosene (previously known as NVC-422) is a broad-spectrum, fast-acting topical anti-infective agent against microbial pathogens, including antibiotic-resistant microbes. It has been investigated in phase II clinical trials for the treatment of bacterial conjunctivitis and as a topical gel in children with impetigo. In addition, using a guinea pig model was shown, that auriclosene was effective in the treatment of dermatophytosis, including onychomycosis.

Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.

Droclidinium is the muscarinic receptors antagonist. It is an anticholinergic, spasmolytic agent.

Racemetirosine is an orally active inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamine. At dosages of 600 to 3500mg daily, it is effective in controlling the hypertensive episodes and symptoms of catecholamine excess in phaeochromocytoma during preparation for surgery. Oral Racemetirosine is well absorbed and absorption appears constant in each individual over a wide dosage range. The drug is largely excreted via the kidneys, but extrarenal elimination has not been studied. Case reports on the clinical use of Racemetirosine in phaeochromocytoma indicate that the drug controls hypertension and symptoms of catecholamine excess in most patients during preparation for surgical removal of a tumor. In some cases, the addition of Racemetirosine to phenoxybenzamine plus propranolol has resulted in adequate control of symptoms previously unresponsive to the adrenergic blocking regimen. Drowsiness and sedation have been the most frequently reported side effects of Racemetirosine treatment.

Prodeconium Bromide is a Decamethylene derivative with neuromuscular blocking activity. Prodeconium Bromide acts as a muscle relaxant of short action and belongs to the group of mixed blocking agents. Its complete effect in man is obtained in 100 sec. and lasts for 7 min. Respiratory paralysis is produced by 1 mg/kg of Prodeconium

Nicafenine, a quinoline derivative, is an analgesic.

Etiocholanone is an androstane neurosteroid. Etiocholanone potentiates GABA-A receptor currents and exerts anticolvunsant properties in rodents. Etiocholanolone demostrates pyrogenic properties.